| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PNAS..10817165C |
| P356 | DOI | 10.1073/PNAS.1111020108 |
| P932 | PMC publication ID | 3193241 |
| P698 | PubMed publication ID | 21969582 |
| P5875 | ResearchGate publication ID | 51691243 |
| P50 | author | Nicholas P J Day | Q28033668 |
| Vanaporn Wuthiekanun | Q28321762 | ||
| Premjit Amornchai | Q28321768 | ||
| Direk Limmathurotsakul | Q28321770 | ||
| Sharon Peacock | Q44172566 | ||
| Narisara Chantratita | Q52730888 | ||
| Matthew Holden | Q56767132 | ||
| Aunchalee Thanwisai | Q96165095 | ||
| Drew A Rholl | Q114434006 | ||
| Hui Hoon Chua | Q114563103 | ||
| P2093 | author name string | Patrick Tan | |
| Herbert P Schweizer | |||
| Wen Fong Ooi | |||
| Bernice Sim | |||
| P2860 | cites work | Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand | Q21092291 |
| Extended-spectrum beta-lactamases: a clinical update | Q24534999 | ||
| Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse | Q24535314 | ||
| Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei | Q24564168 | ||
| Multilocus Sequence Typing and Evolutionary Relationships among the Causative Agents of Melioidosis and Glanders, Burkholderia pseudomallei and Burkholderia mallei | Q28202846 | ||
| An improved screening technique for isolation of pseudomonas pseudomallei from clinical specimens | Q28243592 | ||
| Management of melioidosis | Q28245689 | ||
| Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei | Q28302368 | ||
| Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis | Q31876656 | ||
| Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. | Q33840164 | ||
| Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments | Q33857445 | ||
| Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates | Q34156158 | ||
| Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis | Q34451065 | ||
| Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria | Q34647294 | ||
| Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12 | Q35085145 | ||
| Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections | Q36422855 | ||
| Infections caused by Gram-positive bacteria: a review of the global challenge | Q37600393 | ||
| The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment | Q38961152 | ||
| Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. | Q39426298 | ||
| Short report: a rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis | Q39606126 | ||
| Mechanisms of resistance to cephalosporin antibiotics | Q39685326 | ||
| Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition | Q39776196 | ||
| Temperature-Sensitive Cell Division Mutants of Escherichia coli with Thermolabile Penicillin-Binding Proteins | Q40034464 | ||
| Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis | Q40729565 | ||
| A standard numbering scheme for the class A beta-lactamases | Q42861944 | ||
| Characterization of a laboratory-generated variant of BPS beta-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime | Q44198698 | ||
| On the process of cellular division in Escherichia coli: Nucleotide sequence of the gene for penicillin-binding protein 3 | Q48400826 | ||
| Small-Colony Variants of Pseudomonas aeruginosa in Cystic Fibrosis | Q57542653 | ||
| Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus | Q70448643 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Burkholderia pseudomallei | Q140475 |
| ceftazidime | Q808845 | ||
| P304 | page(s) | 17165-17170 | |
| P577 | publication date | 2011-10-03 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei | |
| P478 | volume | 108 |
| Q36630989 | A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes |
| Q33771536 | An avirulent Burkholderia pseudomallei ∆purM strain with atypical type B LPS: expansion of the toolkit for biosafe studies of melioidosis |
| Q26859041 | Animal models for Francisella tularensis and Burkholderia species: scientific and regulatory gaps toward approval of antibiotics under the FDA Animal Rule |
| Q44423713 | Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis |
| Q40542863 | Antibiotic resistance in Burkholderia species |
| Q37015333 | Bacterial gene loss as a mechanism for gain of antimicrobial resistance. |
| Q34321739 | Burkholderia pseudomallei known siderophores and hemin uptake are dispensable for lethal murine melioidosis |
| Q35049384 | Burkholderia pseudomallei sequencing identifies genomic clades with distinct recombination, accessory, and epigenetic profiles. |
| Q91932999 | Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria |
| Q38040144 | Ceftazidime for respiratory infections |
| Q40281317 | Chitin Oligosaccharide (COS) Reduces Antibiotics Dose and Prevents Antibiotics-Caused Side Effects in Adolescent Idiopathic Scoliosis (AIS) Patients with Spinal Fusion Surgery |
| Q46247493 | Comparative analysis of the Burkholderia cenocepacia K56-2 essential genome reveals cell envelope functions that are uniquely required for survival in species of the genus Burkholderia |
| Q30418432 | Construction of a broad-host-range Tn7-based vector for single-copy P(BAD)-controlled gene expression in gram-negative bacteria |
| Q91754183 | Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei |
| Q41874947 | Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection |
| Q46286684 | Diversity and regulation of intrinsic β-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. |
| Q38036072 | Emergence of antibiotic-resistant extremophiles (AREs). |
| Q34277284 | Evolution of Burkholderia pseudomallei in recurrent melioidosis |
| Q36571985 | Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase |
| Q90238575 | GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens |
| Q90243749 | Human Melioidosis |
| Q36888062 | In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). |
| Q27678056 | Insights into -Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants |
| Q37194316 | Less is more: Burkholderia pseudomallei and chronic melioidosis |
| Q39582866 | Loss of Methyltransferase Function and Increased Efflux Activity Leads to Doxycycline Resistance in Burkholderia pseudomallei |
| Q38066577 | Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis |
| Q57094969 | Melioidosis |
| Q61699558 | Melioidosis |
| Q38070912 | Melioidosis and the kidney |
| Q38259874 | Melioidosis: molecular aspects of pathogenesis. |
| Q36644825 | Membrane-Bound PenA β-Lactamase of Burkholderia pseudomallei |
| Q64916117 | Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. |
| Q38712471 | One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams |
| Q64232507 | Persistent Bacteremia in A Filipino Immigrant to the United States: A Case Report |
| Q35960287 | Rapid Antimicrobial Susceptibility Testing of Bacillus anthracis, Yersinia pestis, and Burkholderia pseudomallei by Use of Laser Light Scattering Technology |
| Q33877994 | Rapid Burkholderia pseudomallei identification and antibiotic resistance determination by bacteriophage amplification and MALDI-TOF MS. |
| Q60044061 | Rapid antimicrobial susceptibility testing and β-lactam-induced cell morphology changes of Gram-negative biological threat pathogens by optical screening |
| Q37553152 | Secondary metabolites from Bacillus amyloliquefaciens isolated from soil can kill Burkholderia pseudomallei |
| Q39446204 | Susceptibility of Clinical Isolates of Burkholderia pseudomallei to a Lipid A Biosynthesis Inhibitor |
| Q35560710 | T Cell Immunity to the Alkyl Hydroperoxide Reductase of Burkholderia pseudomallei: A Correlate of Disease Outcome in Acute Melioidosis |
| Q49025273 | Targeting the nonmevalonate pathway in Burkholderia cenocepacia increases susceptibility to certain β-lactam antibiotics. |
| Q58765448 | The heritable natural competency trait of Burkholderia pseudomallei in other Burkholderia species through comE and crp |
| Q55715517 | Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance. |
| Q36247396 | Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response |
| Q34538191 | Treatment and prophylaxis of melioidosis |
| Q57031012 | Why is the response rate slow in ceftazidime therapy for melioidosis? |
| Q33555304 | Within-Host Evolution of Burkholderia pseudomallei during Chronic Infection of Seven Australasian Cystic Fibrosis Patients |
| Q37074494 | Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection |
| Q36570592 | Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010 |
| Q30458468 | φX216, a P2-like bacteriophage with broad Burkholderia pseudomallei and B. mallei strain infectivity. |
Search more.